To investigate the potential association between carbonic anhydrase inhibitors (CAIs) and mood changes in glaucoma patients, emphasizing the clinical significance of these mood changes.
Key Findings:
Topical CAI use was associated with a 25–35% higher hazard of depression, indicating a significant risk.
There was nearly a twofold increase in the likelihood of antidepressant initiation in the early months after starting CAIs, highlighting the need for monitoring.
Mood changes were evident as early as three months after treatment initiation, suggesting prompt assessment is necessary.
Interpretation:
Ophthalmologists should be more vigilant about monitoring neuropsychiatric symptoms in patients starting topical CAIs, especially in the initial months, and consider implementing routine mood assessments.
Limitations:
The study may not account for all confounding variables influencing mood changes, including patient history and external factors.
Routine screening for depression in clinical settings can be challenging due to time constraints and lack of integrated tools.
Conclusion:
The findings suggest a need for increased awareness of mood-related side effects of CAIs and highlight the importance of integrating mental health considerations into glaucoma care, along with educating patients about potential mood effects.
